<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2020.93014</article-id><article-id pub-id-type="publisher-id">PI-35061</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20200300000_68024247.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  “铁门”靶向抗体研究进展
  Research Progress of “Iron Gate” Targeting Antibody
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>洋</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>煜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>童</surname><given-names>玥</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>中国药科大学生命科学与技术学院，江苏 南京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>04</month><year>2020</year></pub-date><volume>09</volume><issue>03</issue><fpage>92</fpage><lpage>102</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   铁元素作为生命体不可或缺的微量营养素，广泛参与生命体的多种生物功能中，如细胞呼吸、DNA复制、细胞周期、活性氧产生。正常情况下，机体铁稳态受到严格调控。转铁蛋白受体1 (transferrin receptor 1, TFR1)这一“铁门”作为细胞摄取铁的主要途径，在维持机体铁稳态中起关键作用。TFR1表达受到严格调控。研究发现，血脑屏障管腔膜上TFR1表达水平远高于外周毛细血管内皮细胞，这种高表达属性已被证明与维持脑内铁稳态有关。血脑屏障的存在阻挡了绝大多数药物的脑内渗透，低生物利用度使得药物药效无法发挥。TFR1作为血脑屏障管腔膜上的天然膜受体可以介导生物大分子转铁蛋白的转胞吞。目前基于TFR1抗体的药物脑内递送研究主要围绕TFR1抗体跨血脑屏障转运的潜力开发和TFR1抗体相关药物的脑部疾病治疗展开。除此之外，多份研究表明，机体铁过载有助于肿瘤的发生、发展和转移。TFR1作为细胞摄取铁的主要途径，广泛参与这一过程。通过靶向肿瘤细胞这一“铁门”，TFR1抗体已被广泛用于血液恶性肿瘤、胰腺癌等多种恶性肿瘤的诊治中。本文旨在对靶向细胞“铁门”的TFR1抗体在以上两方面的最新研究进展予以论述。 Iron is an indispensable micronutrient for life, and it is widely involved in many biological functions of life, such as cell respiration, DNA replication, cell cycle, and reactive oxygen species production. Under normal circumstances, the body’s iron homeostasis is strictly regulated. The transferrin receptor 1 (TFR1)—“iron gate”, as the main way for cells to take up iron, plays a key role in maintaining iron homeostasis. Expression of TFR1 is strictly regulated. Studies have found that the expression level of TFR1 on the luminal membrane of the blood-brain barrier (BBB) is much higher than that of peripheral capillary endothelial cells. This high expression attribute has been shown to be related to maintaining iron homeostasis in the brain. The presence of the BBB blocks the brain penetration of most drugs, and low bioavailability prevents the drug's efficacy from being exerted. TFR1, as a natural membrane receptor on the luminal membrane of the BBB, can mediate the transcytosis of the biological macromolecule transferrin. At present, the research of TFR1 antibody-based delivery of drugs into the cerebral mainly focuses on the development of the potential of TFR1 antibody to cross the blood-brain barrier and the treatment of brain diseases with TFR1 antibody related drugs. In addition, several studies have shown that iron overload in the body contributes to the occurrence, development, and metastasis of tumor. TFR1, as the main gate for cells to take up iron, is widely involved in this process. By targeting this “iron gate” of tumor cells, TFR1 antibodies have been widely used in the diagnosis and treatment of a variety of malignant tumors including hematological malignancies, pancreatic cancer and so on. This article aims to discuss the latest research progress of the TFR1 antibody targeting the cell “iron gate” in the above two aspects. 
  
 
</p></abstract><kwd-group><kwd>铁稳态，血脑屏障，铁代谢异常，转铁蛋白受体1，转铁蛋白受体1抗体, Iron Homeostasis</kwd><kwd> Blood-Brain Barrier</kwd><kwd> Abnormal Iron Metabolism</kwd><kwd> Transferrin Receptor 1</kwd><kwd> Transferrin Receptor 1 Antibody</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>“铁门”靶向抗体研究进展<sup> </sup></title><p>刘洋，刘煜，童玥<sup>*</sup></p><p>中国药科大学生命科学与技术学院，江苏 南京</p><disp-formula id="hanspub.35061-formula14"><graphic xlink:href="//html.hanspub.org/file/2-1710219x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年3月25日；录用日期：2020年4月8日；发布日期：2020年4月16日</p><disp-formula id="hanspub.35061-formula15"><graphic xlink:href="//html.hanspub.org/file/2-1710219x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>铁元素作为生命体不可或缺的微量营养素，广泛参与生命体的多种生物功能中，如细胞呼吸、DNA复制、细胞周期、活性氧产生。正常情况下，机体铁稳态受到严格调控。转铁蛋白受体1 (transferrin receptor 1, TFR1)这一“铁门”作为细胞摄取铁的主要途径，在维持机体铁稳态中起关键作用。TFR1表达受到严格调控。研究发现，血脑屏障管腔膜上TFR1表达水平远高于外周毛细血管内皮细胞，这种高表达属性已被证明与维持脑内铁稳态有关。血脑屏障的存在阻挡了绝大多数药物的脑内渗透，低生物利用度使得药物药效无法发挥。TFR1作为血脑屏障管腔膜上的天然膜受体可以介导生物大分子转铁蛋白的转胞吞。目前基于TFR1抗体的药物脑内递送研究主要围绕TFR1抗体跨血脑屏障转运的潜力开发和TFR1抗体相关药物的脑部疾病治疗展开。除此之外，多份研究表明，机体铁过载有助于肿瘤的发生、发展和转移。TFR1作为细胞摄取铁的主要途径，广泛参与这一过程。通过靶向肿瘤细胞这一“铁门”，TFR1抗体已被广泛用于血液恶性肿瘤、胰腺癌等多种恶性肿瘤的诊治中。本文旨在对靶向细胞“铁门”的TFR1抗体在以上两方面的最新研究进展予以论述。</p><p>关键词 :铁稳态，血脑屏障，铁代谢异常，转铁蛋白受体1，转铁蛋白受体1抗体</p><disp-formula id="hanspub.35061-formula16"><graphic xlink:href="//html.hanspub.org/file/2-1710219x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-1710219x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-1710219x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>大脑作为人体相对独立的一部分，血脑屏障的存在虽然限制很多大分子物质的进入，但通过血脑屏障管腔膜上各种膜受体对营养物质的转运，大脑的稳态依旧不受影响。转铁蛋白受体1 (transferrin receptor 1, TFR1)在血脑屏障(blood-brain barrier, BBB)管腔膜上表达水平明显高于外周毛细血管内皮细胞，这种高表达属性已被证明与维持脑内铁稳态有关。自从20世纪80年代TFR1抗体产生时起，围绕TFR1抗体靶向BBB管腔膜上TFR1跨血脑屏障转运研究一直在进行。近十年来，随着生物技术的迅速发展，TFR1抗体跨血脑屏障转运被直接证明。随着对TFR1抗体促发的TFR1胞内差异分选机制研究深入，TFR1抗体跨血脑屏障转胞吞的潜力将得到进一步开发，目前已有TFR1抗体相关药物走向临床试验。</p><p>正常情况下，机体各组织TFR1的表达受到严格调控，仅维持基础表达。但在很多肿瘤组织中，铁代谢被重新编程，TFR1表达显著提高。靶向TFR1抑制肿瘤细胞铁摄入已经在多种恶性肿瘤中被证明具有铁耗竭性抑制增殖、促进凋亡的作用。本文将从TFR1抗体应用的基础开始对TFR1抗体的最新研究进展做一综述。</p></sec><sec id="s4"><title>2. 铁元素与铁稳态</title><p>微量元素是生命体不可或缺的微量营养素。铁作为人体内含量最多的微量元素，是人体内很多蛋白发挥活性所必须的组成成分。这些蛋白在人体中具有广泛的生物功能，包括参与细胞呼吸的细胞色素体系、铁硫蛋白；参与与氧有关的氧传感、氧转运、氧代谢的血红蛋白、肌红蛋白、过氧化物酶、过氧化氢酶；参与能量代谢三羧酸循环中的柠檬酸合酶、乌头酸梅、异柠檬酸脱氢酶、琥珀酸脱氢酶；参与DNA合成和修复的核糖核苷酸还原酶、脱氧核糖核酸解旋酶；参与信号转导的一氧化氮合酶、单加氧酶、氧化还原酶等 [<xref ref-type="bibr" rid="hanspub.35061-ref1">1</xref>]。人体内铁稳态受到严格调控。在全身水平上，骨形态发生蛋白–铁调素–铁转运蛋白轴对全身铁稳态进行调节，表现为当机体缺铁时，肝脏铁调素分泌下调，细胞表面铁转运蛋白运铁能力增加，一方面增加食物来源铁在小肠壁细胞向血液循环系统输入，一方面包括巨噬细胞在内的储铁细胞铁输出增加，通过增加外源和內源铁释放使得血液循环系统铁载量增加，反之亦然 [<xref ref-type="bibr" rid="hanspub.35061-ref2">2</xref>]。在细胞水平上，目前研究最透彻的是通过铁调控蛋白–铁蛋白/TFR1轴进行细胞内铁稳态调节，表现为当细胞缺铁时，铁调控蛋白表达增加使TFR1表达增加，增加铁摄取，细胞内储铁铁蛋白表达减少，减少摄入铁的储存，增加细胞代谢用铁，反之亦然 [<xref ref-type="bibr" rid="hanspub.35061-ref3">3</xref>]。</p></sec><sec id="s5"><title>3. 铁代谢异常与肿瘤发生发展</title><p>肿瘤发生是由环境因素和遗传因素共同作用所致。归根结底，肿瘤发生与基因的改变密不可分。正常细胞的生长和增殖受到原癌基因和抑癌基因的共同调节，无论是原癌基因的激活还是抑癌基因的失活都会促发正常细胞的恶性生长，诱导细胞发生癌变。铁元素广泛参与机体生物功能中，如DNA复制、细胞呼吸、细胞周期。但同时铁也参与活性氧(reactive oxygen species, ROS)的产生，如通过细胞呼吸产生的H<sub>2</sub>O<sub>2</sub>及O2<sup>•−</sup>可以和Fe<sup>2+</sup>发生net Haber-Weiss反应产生HO<sup>•</sup>自由基。铁元素同样可以介导脂质ROS的产生。ROS可以诱导DNA碱基修饰和DNA链的断裂。目前认为，过多ROS产生与肿瘤发生密不可分。一份来自于铁与癌症间关系的流行病学数据显示，相比低血液转铁蛋白载铁饱和度，高血液转铁蛋白载铁饱和度致癌风险更高 [<xref ref-type="bibr" rid="hanspub.35061-ref4">4</xref>]。遗传性血色沉着病作为典型的铁过载型疾病，研究表明血色沉着病患者多种癌症发生风险增高，其中肝癌发生率是正常人的20~200倍。Shinya Akatsuka等人通过对过量铁诱发的肾细胞癌基因组进行分析，结果显示广泛的基因组改变，表明由铁介导的ROS过量产生是基因组改变的原因 [<xref ref-type="bibr" rid="hanspub.35061-ref5">5</xref>]。流行病学数据结合肿瘤基因组分析结果都表明铁过载有利于肿瘤发生。铁过载同样可以促进肿瘤的生长，这种促进作用可以通过减少膳食铁摄入、使用铁螯合剂和调控铁代谢相关蛋白如阻碍TFR1介导的铁摄入、促进铁转运蛋白介导的铁输出，失活铁调控蛋白等逆转。铁过载也显示出促进肿瘤转移的作用，Jiabei Wang等人使用铁螯合剂提高了细胞内抑癌基因NDRG2 (N-Myc downstream regulated gene 2)表达水平，从而抑制了肝细胞癌上皮间质转化 [<xref ref-type="bibr" rid="hanspub.35061-ref6">6</xref>]。Wenli Guo等人同样发现铁转运蛋白的过表达阻碍了小鼠的乳腺癌生长以及向肺和肝的转移 [<xref ref-type="bibr" rid="hanspub.35061-ref7">7</xref>]。由此可见，铁元素对于肿瘤的发生、发展和转移都是必不可少的，肿瘤细胞对铁的依赖性甚至可以是上瘾的。针对肿瘤细胞这一特性，靶向铁代谢途径已经被广泛用于疾病诊断、药物研发及预后评估。</p></sec><sec id="s6"><title>4. TFR1和TFR1抗体</title><p>TFR1，亦称作CD71，为一种单程二型跨膜糖蛋白分子，相对分子量约为84 KDa。TFR1在细胞膜上主要以同源二聚体的形式存在，在结构上主要分为氮端胞内区(1-67AA)、跨膜区(68-88AA)和胞外域(89-760AA)。胞内区含有内吞基序(YXRF)，参与内吞。胞外茎区(89-120A)通过两个二硫键将TFR1连成同源二聚体。胞外蛋白酶样结构域(121-188AA, 384-606AA)、螺旋结构域(607-760AA)参与结合载铁转铁蛋白(holo-transferrin, holo-Tf) [<xref ref-type="bibr" rid="hanspub.35061-ref8">8</xref>]。TFR1作为细胞摄取铁的主要途径，可与血液中的holo-Tf结合。holo-Tf-TFR1复合物以网格蛋白介导的内吞向细胞内输送铁元素，进而维持细胞内的铁稳态。正常情况下，TFR1本身受到严格调控，在机体的许多组织中仅有基础表达。目前仅发现在脑毛细血管内皮细胞、肝细胞和快速增殖的细胞上表达增加。除此之外，很多恶性肿瘤细胞表面TFR1表达明显增加。</p><p>依据识别的TFR1部位，TFR1抗体主要分为两大类，一种为靶向TFR1配体结合部位，可以对holo-Tf与TFR1的结合产生竞争性抑制作用。另一种为靶向非配体结合部位，这种非竞争性结合并不会明显阻碍holo-Tf与TFR1的结合。配体竞争性TFR1抗体具有阻碍TFR1向细胞内输送铁的能力，主要应用于抗肿瘤研究。研究表明，配体竞争性TFR1抗体可使高表达TFR1的肿瘤细胞铁耗竭性死亡 [<xref ref-type="bibr" rid="hanspub.35061-ref9">9</xref>]。非配体竞争性TFR1抗体不会影响TFR1正常的运铁功能，对细胞毒性较小，主要应用于跨血脑屏障脑内转运研究。</p></sec><sec id="s7"><title>5. TFR1抗体在跨血脑屏障药物脑内递送方面的研究进展</title><sec id="s7_1"><title>5.1. TFR1抗体跨血脑屏障脑内转运潜力开发</title><p>早期的研究表明，TFR1在啮齿类动物和灵长类动物的脑毛细血管内皮细胞上有功能性表达，且表达量显著高于外周毛细血管内皮细胞。这种高表达属性在脑毛细血管内皮细胞离体培养初始就会丢失，结合脑内TFR1广泛存在这一事实，说明脑毛细血管内皮细胞上TFR1表达增加在维持脑内铁稳态方面具有重要作用 [<xref ref-type="bibr" rid="hanspub.35061-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.35061-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.35061-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.35061-ref13">13</xref>]。早期的同位素示踪实验已经证明，无论是铁元素还是转铁蛋白(transferrin, Tf)都可以被高度选择性内吞入脑毛细血管内皮细胞，只不过两者在细胞内的命运不同。铁元素在细胞内被富集随后很快分散于脑实质中，有关铁元素由内皮细胞进入脑实质的机制目前依旧处于研究中。Tf在内皮细胞中的饱和度远远小于铁元素，这种现象与受体介导的转包吞相符，不过Tf-TFR1复合物在脑毛细血管内皮细胞内转包吞确切路径目前依旧不是很清楚 [<xref ref-type="bibr" rid="hanspub.35061-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.35061-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.35061-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.35061-ref16">16</xref>]。从21世纪开始，研究者对TFR1抗体跨血脑屏障脑内转运能力进行了广泛的研究，如早期设计靶向TFR1非配体结合部位的TFR1抗体(8D3, OX26)。8D3为一种大鼠来源针对小鼠TFR1的非配体竞争性抗体。OX26为一种小鼠来源针对大鼠TFR1的非配体竞争性抗体。非配体竞争性旨在不影响受体功能和BBB完整性的同时，希望通过TFR1介导的转包吞作用实现TFR1抗体脑内渗透。虽然Pardridge WM [<xref ref-type="bibr" rid="hanspub.35061-ref17">17</xref>] 等人将8D3作为药物转运载体明显增强了中风 [<xref ref-type="bibr" rid="hanspub.35061-ref18">18</xref>]、阿尔兹海默症 [<xref ref-type="bibr" rid="hanspub.35061-ref19">19</xref>]、帕金森病 [<xref ref-type="bibr" rid="hanspub.35061-ref20">20</xref>]、黏多糖贮积症 [<xref ref-type="bibr" rid="hanspub.35061-ref21">21</xref>] 等中枢神经系统疾病治疗药物小鼠脑内药效，但这些实验中缺乏直接证据表明TFR1抗体脑实质的广泛存在。这些实验缺少恰当的同型对照，同时不可忽略的抗8D3抗体在长期给药过程中的存在是否会对BBB完整性产生破坏进而影响实验结果这一点也没有得到验证。后期Gemma Manich等人的实验验证了8D3脑毛细血管内皮细胞的靶向性，但同时确认8D3无法有效实现向远腔侧转移，并且随着时间的推移8D3趋向于胞内降解。同样地，OX26也被证明更趋向于胞内降解 [<xref ref-type="bibr" rid="hanspub.35061-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.35061-ref23">23</xref>]。</p><p>近十年来，研究者针对8D3、OX26等高亲和力抗体较低水平的脑内渗透原因提出了多种假设，并对这些假设进行了实验验证。Jens Niewoehner等人提出抗体价态可能在TFR1抗体跨血脑屏障转运中起到重要作用。天然配体的单价结合转包吞模式可能会被抗体双价结合模式打破，造成TFR1间的广泛交联，最终导致抗体滞留在细胞内走向溶酶体降解途径。这种假设在针对TFR1的单价抗体结合模式中得到了验证，实验中TFR1单价抗体更倾向于向远腔侧转运，具有更广泛的脑内暴露。单价抗体内吞后与溶酶体标志物共定位情况符合天然配体正常溶酶体降解命运，成功使运载的药物脑内暴露量增加了一个数量级，而正常双价抗体仅仅被发现定位于脑毛细血管内皮细胞内，与溶酶体共定位率超过了50%。这些结果表明TFR1抗体价态影响TFR1细胞内分选及命运 [<xref ref-type="bibr" rid="hanspub.35061-ref24">24</xref>]。Y. Joy Yu等人提出了另一种假设，认为抗体的亲和力可能影响TFR1胞内转运，最终影响TFR1和抗体细胞内命运。作者通过对TFR1双价抗体和TFR1单价抗体进行亲和力改造，证明了无论是单价还是双价高亲和力抗体相比低亲和力单/双价抗体趋向于引起更多的TFR1内吞后降解。增加的TFR1降解显著减少TFR1的循环和BBB管腔膜上TFR1密度，这些可能最终导致高亲和力TFR1抗体脑内暴露减少。相比而言，低亲和力TFR1抗体更多地保持了TFR1正常胞内转运路径，显著增加TFR1抗体脑内暴露 [<xref ref-type="bibr" rid="hanspub.35061-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.35061-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.35061-ref27">27</xref>]。除了TFR1抗体亲和力和价态对TFR1内化后分选途径产生影响外，抗体的pH敏感性也被认为对TFR1内化后命运产生影响。Hadassah Sade等人通过比较两个亲和力相当的TFR1抗体内吞入脑毛细血管内皮细胞后命运发现，在低pH下亲和力降低的抗体可以实现有效的转包吞，如同天然配体的转包吞一样，而pH不敏感的抗体则明显滞留在内皮细胞中最终被降解。这种pH敏感型抗体转包吞可以被内体酸化抑制剂所抑制。这些结果表明抗体在进入内体后因pH敏感性使之在内体酸性增加的条件下更趋向与TFR1解离，这有助于抗体摆脱降解命运，胞吐出细胞 [<xref ref-type="bibr" rid="hanspub.35061-ref28">28</xref>]。除此之外，TFR1抗体识别的表位也可能会对TFR1内吞及胞内分选途径产生影响，因为从目前已知的Tf-TFR1复合物转包吞机制来看，无论是Tf与TFR1的结合，还是Tf-TFR1复合物内吞后内体酸化，TFR1本身一直经历蛋白空间结构的变化，而这种结构变化可能正是促发相应内吞及内体分选的关键信号，TFR1抗体与TFR1间的相互作用可能影响TFR1这一过程中正常的结构变化。相信随着对受体介导的转包吞机制研究深入，TFR1抗体跨血脑屏障转运潜力将会得到更大的开发。</p></sec><sec id="s7_2"><title>5.2. 在脑部疾病治疗中的应用</title><p>血脑屏障阻挡外源病原体进入大脑的同时也阻挡了几乎所有生物大分子和超过98%小分子物质进入脑内。针对脑部疾病，虽然有很多候选药已经进入临床，如用于治疗肌萎缩性脊髓侧索硬化症的脑源性神经营养因子(brain-derived neurotrophic factor, BDNF) [<xref ref-type="bibr" rid="hanspub.35061-ref29">29</xref>]、睫状神经营养因子(ciliary neurotrophic factor, CNTF) [<xref ref-type="bibr" rid="hanspub.35061-ref30">30</xref>]；用于治疗脑卒中的碱性成纤维细胞生长因子(basic fibroblast growth factor, bFGF) [<xref ref-type="bibr" rid="hanspub.35061-ref31">31</xref>]、促红细胞生成素(erythropoietin, EPO) [<xref ref-type="bibr" rid="hanspub.35061-ref32">32</xref>]；用于治疗帕金森病(Parkinson’s disease, PD)的胶质细胞源神经营养因子(glialcellline-derived neurotrophic factor, GDNF) [<xref ref-type="bibr" rid="hanspub.35061-ref33">33</xref>]；用于治疗阿尔茨海默病(Alzheimer disease, AD)的bapineuzumab [<xref ref-type="bibr" rid="hanspub.35061-ref34">34</xref>] 等。但由于缺少足够的脑内渗透，导致这些药物的临床治疗效果都不是很理想。药物要想发挥作用需要与靶标直接接触并且达到药效浓度。Yu YJ团队在之前的工作中已经验证了降低亲和力的TFR1抗体脑内生物利用度的显著提高。β分泌酶(BACE1)作为一种天冬氨酰蛋白酶，其有助于β淀粉样肽形成，是阿尔兹海默症治疗有效的靶点之一。研究表明，靶向TFR1和BACE1的双特性抗体(anti-TFR1/BACE1)无论是在hTFR1转基因小鼠还是在食蟹猴中都显示出高于亲本BACE1抗体的脑渗透和抑制β淀粉样肽产生的能力。同时该抗体并未对食蟹猴造血系统和全身铁稳态产生较大影响 [<xref ref-type="bibr" rid="hanspub.35061-ref35">35</xref>]。黏多糖贮积症II (MPSII)为一种X染色体隐性遗传病，主要起于艾杜糖醛酸-2-硫酸酯酶(IDS)基因突变所致的IDS酶活丧失，引起包括硫酸乙酰肝素(HS)和硫酸皮肤素(DS)在内的糖胺聚糖(GAGs)全身累积。目前该病的主要治疗方法为酶替代疗法，但传统的酶替代疗法无法实现脑内治疗。Hiroyuki Sonoda等研究人员将hIDS与hTFR1抗体融合，融合蛋白JR-141在3 mg/kg静脉注射剂量下，不仅使MPS II模型小鼠外周组织GAGs水平恢复正常，而且克服了传统酶替代疗法无法实现脑内治疗的局限，使大脑中GAGs水平降低到接近正常水平，MPSII相关中枢神经系统症状得到明显缓解 [<xref ref-type="bibr" rid="hanspub.35061-ref36">36</xref>]。已完成的JR-141治疗MPS II的I/II期临床试验结果显示，以每周2 mg/kg剂量静脉给予JR-141，持续四周，安全且耐受性良好。四周疗程后患者脑内硫酸乙酰肝素(HS)相对治疗初始减少了约31.5% &#177; 3.9%，部分患者表现出运动和行为的改善 [<xref ref-type="bibr" rid="hanspub.35061-ref37">37</xref>]。</p><p>多形性胶质母细胞瘤(glioblastoma multiforme, GBM)是成人中最具侵袭性和致死性的脑肿瘤。外科手术切除和放化疗联合治疗依旧是目前最经典的方法，但GBM患者预后仍然较差。不良预后除了跟GBM自身的高侵袭性和浸润性有关外，还跟药物抗性密不可分。GBM对标准化学治疗剂替莫唑胺(Temozolomide, TMZ)的抗性目前认为主要是跟GBM细胞O6-甲基鸟嘌呤-DNA-甲基转移酶(MGMT)的过表达有关。因为该酶可以通过去除鸟嘌呤O6位上的简单烷基来修复TMZ诱导的DNA损伤。许多研究已经表明，增加p53抑癌基因表达可以下调DNA修复基因(如MGMT)的表达，增加肿瘤细胞对烷化剂的敏感性。Sang-Soo Kim团队通过将p53基因表达质粒封装于TFR1单链可变区抗体(TFR1scfv)修饰的脂质体中，构建好的免疫脂质体SGT-53已被证明可以实现脑内递送，有效降低GBM细胞内MGMT的表达。研究表明，SGT-53可以有效克服GBM对TMZ的抗性，SGT-53与TMZ联合给药可以增加GBM对TMZ的敏感性，显著延长GBM模型小鼠的生存期，甚至使肿瘤消退 [<xref ref-type="bibr" rid="hanspub.35061-ref38">38</xref>] [<xref ref-type="bibr" rid="hanspub.35061-ref39">39</xref>]。目前SGT-53和TMZ联合用于治疗GBM的二期临床试验已经结束，不过临床数据尚未公布。M.J. Ramalho等人使用OX26修饰的聚乳酸–乙醇酸共聚物(PLGA)纳米颗粒(NPs)包封TMZ，构建好的TMZ-loaded mAb-PLGA NPs免疫纳米颗粒显著增强TMZ对GBM的细胞毒性，同时OX26的存在降低了TMZ对BBB完整性的损伤 [<xref ref-type="bibr" rid="hanspub.35061-ref40">40</xref>]。创新型纳米材料的迅速发展，使针对人体深部组织的远程物理刺激成为可能，比如在纳米肿瘤学领域应用的光热、光动力、磁热和机械能电能转换的纳米材料。这些纳米材料已被广泛用于开发治疗肿瘤的新疗法。压电纳米颗粒是一种可以实现机械能和电能相互转换的纳米材料，Attilio Marino等人用TFR1抗体修饰压电纳米材料钛酸钡纳米颗粒(BTNPs)，产生的AbBTNP实现了血脑屏障和脑胶质瘤的双重靶向。实验证明，在外界超声波的机械能激发下，BTNP转化的电能可以对脑胶质瘤增殖产生抑制作用，促进其凋亡。AbBTNP与TMZ联合给药具有协同作用，可以明显增强脑胶质瘤对TMZ的敏感性，体外实验显示出增强的抗肿瘤能力 [<xref ref-type="bibr" rid="hanspub.35061-ref41">41</xref>]。不可否认，TFR1抗体的存在使得这些药物的脑部生物利用度得到显著提高，显著增加了药物的治疗潜力。随着TFR1抗体转包吞潜力的进一步开发，TFR1介导的转包吞有希望成为药物脑内递送安全可靠的途径。</p></sec></sec><sec id="s8"><title>6. 在脑外肿瘤诊治中的应用</title><sec id="s8_1"><title>6.1. 在血液恶性肿瘤诊治中的应用</title><p>免疫疗法尤其是抗体介导的抗肿瘤疗法在血液恶性肿瘤治疗中的应用越来越广泛，诸如靶向CD38 和SLAMF7的达雷木单抗和埃罗妥珠单抗，均于2015年被FDA批准用于多发性骨髓瘤的治疗。CCR4靶向的mogamulizumab也于2018年被FDA批准用于皮肤T细胞淋巴瘤的治疗中。这些抗体抗肿瘤作用的发挥主要是依靠抗体Fc段的效应功能。虽然我们已经在战胜血液恶性肿瘤的道路上迈出了一大步，但更具治疗潜力靶标抗体的开发依旧是刻不容缓。研究发现，TFR1在多种血液恶性肿瘤中呈现高表达。Manuel L. Penichet等人将hTFR1抗体(ch128.1)应用于恶性B细胞多发性骨髓瘤治疗中，结果显示ch128.1对恶性B细胞多发性骨髓瘤具有异常高的抗肿瘤活性 [<xref ref-type="bibr" rid="hanspub.35061-ref42">42</xref>] [<xref ref-type="bibr" rid="hanspub.35061-ref43">43</xref>]。除此之外，Tracy R. Daniels-Wells等人在B细胞非霍奇金淋巴瘤(AIDS-NHL)异种移植小鼠中也观察到ch128.1显著的抗肿瘤作用 [<xref ref-type="bibr" rid="hanspub.35061-ref44">44</xref>]。值得注意的是，靶向TFR1所发挥的抗肿瘤作用可以依赖于两个独立机制，一种即为依靠抗体Fc段的效应功能，另一种是由中和作用引起的细胞内铁耗竭效应。这种协同作用被Shunsuke Shimosaki等人印证。研究结果表明，无论是在免疫缺陷或免疫系统健全小鼠体内，TFR1抗体(JST-TFR09)均展现出强烈的抗肿瘤能力，免疫系统健全下肿瘤基本消退。相比而言，mogamulizumab仅在免疫系统健全时对皮肤T细胞淋巴瘤的生长起到温和的抑制作用 [<xref ref-type="bibr" rid="hanspub.35061-ref45">45</xref>]。TFR1抗体在红白血病的治疗中也展现出很高潜力 [<xref ref-type="bibr" rid="hanspub.35061-ref9">9</xref>]。这些研究表明TFR1极有希望成为血液恶性肿瘤广谱生物标志物，显示出TFR1抗体在血液恶性肿瘤诊治方面的巨大潜力。</p></sec><sec id="s8_2"><title>6.2. 在胰腺癌诊治中的应用</title><p>胰腺癌侵袭性强，预后差，患者5年生存率不足10%，是全球与癌症相关死亡的第七大主要原因[<xref ref-type="bibr" rid="hanspub.35061-ref46">46</xref>]。目前治疗方法依旧是以手术切除治疗为主，但由于胰腺癌早期缺乏典型的临床表现，无特异症状，使得患者确诊时往往已处于晚期，癌细胞已经发生扩散，适合进行手术切除治疗的患者比例少之又少。研究表明，胰腺癌中80%具有KRAS突变，目前设计针对RAS-RAF-MEK-ERK MAPK信号通路及其下游相关信号转导通路的靶向抑制剂有很多已经走向了临床试验，如ERK抑制剂(SCH772984)、MEK抑制剂(trametinib)等。MYC处于RAS-RAF-MEK-ERK MAPK信号通路下游，MYC的激活将导致TFR1的表达上调。TFR1有可能成为MAPK信号通路依赖型胰腺癌生物标志物。Kelly E. Henry等人证明了TFR1在评估MARP通路靶向抑制剂胰腺癌治疗响应方面的能力。作者通过对胰腺癌模型小鼠使用TFR1靶向探针进行正电子发射断层扫描(Positron Emission Computed Tomography, PET)成像，成功反映出BRD4、ERK抑制剂胰腺癌治疗响应程度 [<xref ref-type="bibr" rid="hanspub.35061-ref47">47</xref>]。这些结果表明TFR1靶向探针可以对MARP通路依赖型胰腺癌药物治疗情况进行即时评估，具有指导临床分层加快胰腺癌治疗药物临床试验进程的潜力。针对TFR1开发的67Ga-citrate-Tf放射性探针已被用于评估TFR1表达，但具有更高特异性和更高亲和力的TFR1抗体更能真实反应TFR1的表达和分布情况，这一点已在Aya Sugyo等人做的对比试验中得到证明 [<xref ref-type="bibr" rid="hanspub.35061-ref48">48</xref>]。Aya Sugyo等人在胰腺癌异种移植小鼠中证实了TFR1抗体对高表达TFR1的胰腺癌的靶向示踪能力 [<xref ref-type="bibr" rid="hanspub.35061-ref49">49</xref>]，并且以此靶向探针设计的放射性免疫制剂也在高表达TFR1的胰腺癌治疗中显示出明显的抗肿瘤作用 [<xref ref-type="bibr" rid="hanspub.35061-ref50">50</xref>]。虽然TFR1抗体的放射性免疫疗法局部杀伤力不如X射线疗法，但若针对晚期癌细胞扩散的胰腺癌将显示出巨大的潜力。此外，以TFR1抗体介导的靶向基因疗法也在胰腺癌的治疗中表现出很大潜力。ER Camp等人以TFR1scfv修饰的脂质体包封p53基因表达质粒，形成的免疫脂质体SGT-53成功实现在转移性胰腺癌中p53基因特异性表达。SGT-53和吉西他滨联合治疗，增加了胰腺癌对吉西他滨的敏感性，明显抑制胰腺癌向肝脏转移。吉西他滨和SGT-53联合治疗转移性胰腺癌的二期临床试验正在进行 [<xref ref-type="bibr" rid="hanspub.35061-ref51">51</xref>]。</p></sec></sec><sec id="s9"><title>7. 在液体活检方面的应用</title><p>液体活检是一种无创、非侵入性血液样品检测技术。微流控芯片技术作为捕获细胞的一种方法，其原理是在芯片的微柱上固定特异性亲和配体，样品流过芯片从而对目的细胞进行捕获。但目前该方法的局限在于只能用特异性亲和力配体筛选特定亚型的肿瘤细胞，这往往需要研究人员和临床医生事先获得待分离肿瘤细胞的亚型特征，这往往是耗时而且高成本的。因此目前仍需要一种精简的肿瘤细胞检测方法，在没有对肿瘤细胞有先验知识的情况下，保留目前肿瘤检测方法的灵敏性和选择性，从血样中筛选出肿瘤细胞。TFR1在多种肿瘤细胞表面高表达，且蛋白表达密度跟肿瘤进展呈现正相关，是一种非常有价值的广谱肿瘤细胞生物标志物 [<xref ref-type="bibr" rid="hanspub.35061-ref52">52</xref>]。Wenjie Li等研究人员使用TFR1抗体包被的微流控芯片对模拟的急性白血病血样进行淋巴母细胞分离，结果显示其分离能力强于急性成淋巴细胞白血病细胞特异性抗体(CD7, CD10)。在急性成淋巴细胞白血病(ALL)细胞占白细胞总数7%的情况下，分离的急性成淋巴细胞白血病细胞纯度达到80%以上。在急性成淋巴细胞白血病细胞(COG-LL-332, COG-LL-317)占白细胞总数只有1%的情况下，分离纯度依旧分别保持在80%~97%、57%~92% [<xref ref-type="bibr" rid="hanspub.35061-ref53">53</xref>]。Veronica J. Lyons和Dimitri Pappas将TFR1抗体应用于急性成骨髓细胞白血病(AML)血样的筛选中，使用TFR1抗体作为AML检测的亲和力配体成功分离出白血病细胞，最高产生92%和62%的捕获效率和纯度 [<xref ref-type="bibr" rid="hanspub.35061-ref54">54</xref>]。</p><p>除此之外，TFR1抗体也可以用于孕妇产前诊断。目前主流的孕妇产前诊断方法主要为羊膜穿刺术取样、绒毛膜绒毛取样。但是这两种侵入性取样方法都有可能造成羊膜内或胚胎感染甚至流产。Huimin Zhang等研究人员开发出针对孕妇血液中循环胚胎有核红细胞的微流控芯片。该芯片以TFR1抗体为亲和力配体对血样中循环有核红细胞的富集可以达到90%。在其应用的三组受试者(18名孕妇、5名未孕女孩和5名产后母亲)中，只有孕妇血样中被检出循环胚胎有核红细胞。通过对筛选出的细胞进行DNA测序分析就可以鉴定胚胎来源、确定胚胎是否存在先天性缺陷 [<xref ref-type="bibr" rid="hanspub.35061-ref55">55</xref>]。无论是在孕妇产前诊断，还是在急性白血病的诊断检测中，以TFR1抗体构建起的亲和力筛选方法都展现出很大潜力。</p></sec><sec id="s10"><title>8. 总结与展望</title><p>不可否认，TFR1抗体介导的脑内药物递送极大增强了药物脑内生物利用度，有助于提高药物治疗指数。目前进入临床的以TFR1抗体进行脑内递送的药物JR-141、SGT-53已完成二期临床试验。JR-141治疗MPS II临床效果良好，SGT-53与TMZ联合治疗脑胶质瘤也展现巨大潜力。相信随着对TFR1在BBB管腔膜上介导的转包吞机制的深入了解和更多新型纳米载体的开发，无论是药物跨血脑屏障转包吞效率，还是药物载量上都会得到很大提高，脑部疾病治疗最大的屏障终将被攻克。除此之外，TFR1抗体在脑部之外的疾病诊治中也表现出很大潜力，高代谢的肿瘤细胞无论是对物质和能量的需求都远远高于正常细胞，TFR1作为细胞摄取铁的主要途径，在多种恶性肿瘤中呈现高表达。针对TFR1开发的免疫探针、免疫毒素、重组抗体、免疫脂质体、免疫纳米颗粒等在血液恶性肿瘤、胰腺癌等恶性肿瘤的诊治中表现出巨大潜力。</p><p>当然，TFR1在造血干细胞等快速增殖的正常细胞上也呈现高表达，TFR1抗体的使用不可避免的会对这些细胞产生一定影响。以TFR1抗体开发的靶向药物需要在临床前进行充分的安全性评估，这可能是TFR1抗体相关药品走向临床使用的最大考验。但同时也有相应的机遇存在，比如通过将TFR1抗体与基因疗法结合，通过抑制致癌基因，激活抑癌基因等，实现对肿瘤细胞的双重甚至多重靶向。SGT-53就是以TFR1抗体结合p53抑癌基因构建起的靶向基因疗法。临床实验表明，SGT-53在自身抗肿瘤作用的基础上，还可以增加肿瘤细胞对其他抗肿瘤药物的敏感性，逆转耐药性。可以预见，依托TFR1抗体的靶向基因疗法将在多种恶性肿瘤治疗中发挥更大作用。</p></sec><sec id="s11"><title>文章引用</title><p>刘 洋,刘 煜,童 玥. “铁门”靶向抗体研究进展Research Progress of “Iron Gate” Targeting Antibody[J]. 药物资讯, 2020, 09(03): 92-102. https://doi.org/10.12677/PI.2020.93014</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.35061-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Crichton, R. (2016) The Essential Role of Iron in Biology. John Wiley &amp; Sons Ltd., New York.</mixed-citation></ref><ref id="hanspub.35061-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Torti, S.V. and Torti, F.M. (2013) Iron and Cancer: More Ore to Be Mined. Nature Reviews Cancer, 13, 342-355.  
&lt;br&gt;https://doi.org/10.1038/nrc3495</mixed-citation></ref><ref id="hanspub.35061-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, D.L., Ghosh, M.C. and Rouault, T.A. (2014) The Physiological Functions of Iron Regulatory Proteins in Iron Homeostasis: An Update. Frontiers in Pharmacology, 5, 124. &lt;br&gt;https://doi.org/10.3389/fphar.2014.00124</mixed-citation></ref><ref id="hanspub.35061-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Stevens, R.G., Graubard, B.I., Micozzi, M.S., et al. (2000) Moder-ate Elevation of Body Iron Level and Increased Risk of Cancer Occurrence and Death, Hepatitis B and the Prevention of Primary Cancer of The Liver. Selected Publications of Baruch S Blumberg, World Scientific, Singapore, 447-452. &lt;br&gt;https://doi.org/10.1142/9789812813688_0045</mixed-citation></ref><ref id="hanspub.35061-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Akatsuka, S., Yamashita, Y., Ohara, H., et al. (2012) Fenton Reaction Induced Cancer in Wild Type Rats Recapitulates Genomic Alterations Observed in Human Cancer. PLoS ONE, 7, e43403. &lt;br&gt;https://doi.org/10.1371/journal.pone.0043403</mixed-citation></ref><ref id="hanspub.35061-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Yin, D., Xie, C., et al. (2014) The Iron Chelator Dp44mT Inhibits Hepatocellular Carcinoma Metastasis via N-Myc Downstream-Regulated Gene 2 (NDRG2)/gp130/STAT3 Pathway. Oncotarget, 5, 8478. 
&lt;br&gt;https://doi.org/10.18632/oncotarget.2328</mixed-citation></ref><ref id="hanspub.35061-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Guo, W., Zhang, S., Chen, Y., et al. (2015) An Important Role of the Hepcidin-Ferroportin Signaling in Affecting Tumor Growth and Metastasis. Acta biochimica et biophysica Sinica, 47, 703-715. &lt;br&gt;https://doi.org/10.1093/abbs/gmv063</mixed-citation></ref><ref id="hanspub.35061-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Eckenroth, B.E., Steere, A.N., Chasteen, N.D., et al. (2011) How the Binding of Human Transferrin Primes the Transferrin Receptor Potentiating Iron Release at Endosomal pH. Proceedings of the National Academy of Sciences, 108, 13089-13094. &lt;br&gt;https://doi.org/10.1073/pnas.1105786108</mixed-citation></ref><ref id="hanspub.35061-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Neiveyans, M., Melhem, R., Arnoult, C., et al. (2019) A Recycling Anti-Transferrin Receptor-1 Monoclonal Antibody as an Efficient Therapy for Erythroleukemia through Target Up-Regulation and Antibody-Dependent Cytotoxic Effector Functions. MAbs, 593-605. &lt;br&gt;https://doi.org/10.1080/19420862.2018.1564510</mixed-citation></ref><ref id="hanspub.35061-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Jefferies, W.A., Brandon, M.R., Hunt, S.V., et al. (1984) Transferrin Receptor on Endothelium of Brain Capillaries. Nature, 312, 162-163. &lt;br&gt;https://doi.org/10.1038/312162a0</mixed-citation></ref><ref id="hanspub.35061-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Pardridge, W.M., Eisenberg, J. and Yang, J. (1987) Human Blood-Brain Barrier Transferrin Receptor. Metabolism, 36, 892-895. &lt;br&gt;https://doi.org/10.1016/0026-0495(87)90099-0</mixed-citation></ref><ref id="hanspub.35061-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Skarlatos, S., Yoshikawa, T. and Pardridge, W.M. (1995) Transport of [125I]Transferrin through the Rat Blood-Brain Barrier. Brain Research, 683, 164-171. &lt;br&gt;https://doi.org/10.1016/0006-8993(95)00363-U</mixed-citation></ref><ref id="hanspub.35061-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Friden, P.M., Walus, L.R., Musso, G.F., et al. (1991) An-ti-Transferrin Receptor Antibody and Antibody-Drug Conjugates Cross the Blood-Brain Barrier. Proceedings of the National Academy of Sciences, 88, 4771-4775.  
&lt;br&gt;https://doi.org/10.1073/pnas.88.11.4771</mixed-citation></ref><ref id="hanspub.35061-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Hersom, M., Helms, H.C., Pretzer, N., et al. (2016) Transferrin Re-ceptor Expression and Role in Transendothelial Transport of Transferrin in Cultured Brain Endothelial Monolayers. Molecular and Cellular Neuroscience, 76, 59-67. 
&lt;br&gt;https://doi.org/10.1016/j.mcn.2016.08.009</mixed-citation></ref><ref id="hanspub.35061-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Morris, C., Keith, A., Edwardson, J., et al. (1992) Uptake and Distribution of Iron and Transferrin in the Adult Rat Brain. Journal of Neurochemistry, 59, 300-306. &lt;br&gt;https://doi.org/10.1111/j.1471-4159.1992.tb08904.x</mixed-citation></ref><ref id="hanspub.35061-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Fishman, J., Rubin, J., Handrahan, J., et al. (1987) Re-ceptor-Mediated Transcytosis of Transferrin across the Blood-Brain Barrier. Journal of Neuroscience Research, 18, 299-304. &lt;br&gt;https://doi.org/10.1002/jnr.490180206</mixed-citation></ref><ref id="hanspub.35061-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Lee, H.J., Engelhardt, B., Lesley, J., et al. (2000) Targeting Rat Anti-Mouse Transferrin Receptor Monoclonal Antibodies through Blood-Brain Barrier in Mouse. Journal of Pharmacology and Experimental Therapeutics, 292, 1048-1052.</mixed-citation></ref><ref id="hanspub.35061-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Fu, A., Hui, E.K.-W., Lu, J.Z., et al. (2011) Neuroprotection in Stroke in the Mouse with Intravenous Erythropoietin-Trojan Horse Fusion Protein. Brain Research, 1369, 203-207. &lt;br&gt;https://doi.org/10.1016/j.brainres.2010.10.097</mixed-citation></ref><ref id="hanspub.35061-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Q.H., Fu, A., Boado, R.J., et al. (2011) Receptor-Mediated Abeta Amyloid Antibody Targeting to Alzheimer’s Disease Mouse Brain. Molecular Pharmacology, 8, 280-285. &lt;br&gt;https://doi.org/10.1021/mp1003515</mixed-citation></ref><ref id="hanspub.35061-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Q.H., Hui, E.K., Lu, J.Z., et al. (2011) Brain Penetrating IgG-Erythropoietin Fusion Protein Is Neuroprotective Following Intravenous Treatment in Parkinson’s Disease in the Mouse. Brain Research, 1382, 315-320. 
&lt;br&gt;https://doi.org/10.1016/j.brainres.2011.01.061</mixed-citation></ref><ref id="hanspub.35061-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Boado, R.J., Hui, E.K., Lu, J.Z., et al. (2011) Reversal of Ly-sosomal Storage in Brain of Adult MPS-I Mice with Intravenous Trojan Horse-Iduronidase Fusion Protein. Molecular Pharmacology, 8, 1342-1350.  
&lt;br&gt;https://doi.org/10.1021/mp200136x</mixed-citation></ref><ref id="hanspub.35061-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Manich, G., Cabezón, I., Del Valle, J., et al. (2013) Study of the Transcytosis of an Anti-Transferrin Receptor Antibody with a Fab’cargo across the Blood-Brain Barrier in Mice. Eu-ropean Journal of Pharmaceutical Sciences, 49, 556-564. &lt;br&gt;https://doi.org/10.1016/j.ejps.2013.05.027</mixed-citation></ref><ref id="hanspub.35061-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Paterson, J. and Webster, C.I. (2016) Exploiting Transferrin Receptor for Delivering Drugs across the Blood-Brain Barrier. Drug Discovery Today: Technologies, 20, 49-52. &lt;br&gt;https://doi.org/10.1016/j.ddtec.2016.07.009</mixed-citation></ref><ref id="hanspub.35061-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Niewoehner, J., Bohrmann, B., Collin, L., et al. (2014) Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle. Neuron, 81, 49-60. &lt;br&gt;https://doi.org/10.1016/j.neuron.2013.10.061</mixed-citation></ref><ref id="hanspub.35061-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Bien-Ly, N., Yu, Y.J., Bumbaca, D., et al. (2014) Transferrin Receptor (TfR) Trafficking Determines Brain Uptake of TfR Antibody Affinity Variants. Journal of Experimental Medicine, 211, 233-244.  
&lt;br&gt;https://doi.org/10.1084/jem.20131660</mixed-citation></ref><ref id="hanspub.35061-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Yu, Y.J., Zhang, Y., Kenrick, M., et al. (2011) Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target. Science Translational Medicine, 3, 84ra44.  
&lt;br&gt;https://doi.org/10.1126/scitranslmed.3002230</mixed-citation></ref><ref id="hanspub.35061-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Haqqani, A.S., Thom, G., Burrell, M., et al. (2018) Intracellular Sorting and Transcytosis of the Rat Transferrin Receptor Antibody OX26 across the Blood-Brain Barrier in Vitro Is Dependent on Its Binding Affinity. Journal of Neurochemistry, 146, 735-752. &lt;br&gt;https://doi.org/10.1111/jnc.14482</mixed-citation></ref><ref id="hanspub.35061-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Sade, H., Baumgartner, C., Hugenmatter, A., et al. (2014) A Human Blood-Brain Barrier Transcytosis Assay Reveals Antibody Transcytosis Influenced by pH-Dependent Receptor Binding. PLoS ONE, 9, e96340. 
&lt;br&gt;https://doi.org/10.1371/journal.pone.0096340</mixed-citation></ref><ref id="hanspub.35061-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">The BDNF Study Group (1999) A Controlled Trial of Recom-binant Methionyl Human BDNF in ALS: The BDNF Study Group (Phase III). Neurology, 52, 1427-1433. &lt;br&gt;https://doi.org/10.1212/WNL.52.7.1427</mixed-citation></ref><ref id="hanspub.35061-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Miller, R.G., Petajan, J.H., Bryan, W.W., et al. (1996) A Place-bo-Controlled Trial of Recombinant Human Ciliary Neurotrophic (rhCNTF) Factor in Amyotrophic Lateral Sclerosis. rhCNTF ALS Study Group. Annals of Neurology, 39, 256-260. &lt;br&gt;https://doi.org/10.1002/ana.410390215</mixed-citation></ref><ref id="hanspub.35061-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Bogousslavsky, J., Victor, S.J., Salinas, E.O., et al. (2002) Fiblast (Trafermin) in Acute Stroke: Results of the European-Australian Phase II/III Safety and Efficacy Trial. Cerebrovascular Diseases, 14, 239-251. 
&lt;br&gt;https://doi.org/10.1159/000065683</mixed-citation></ref><ref id="hanspub.35061-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Ehrenreich, H., Weissenborn, K., Prange, H., et al. (2009) Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke. Stroke, 40, e647-e656. &lt;br&gt;https://doi.org/10.1161/STROKEAHA.109.564872</mixed-citation></ref><ref id="hanspub.35061-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Nutt, J.G., Burchiel, K.J., Comella, C.L., et al. (2003) Randomized, Double-Blind Trial of Glial Cell Line-Derived Neurotrophic Factor (GDNF) in PD. Neurology, 60, 69-73. &lt;br&gt;https://doi.org/10.1212/WNL.60.1.69</mixed-citation></ref><ref id="hanspub.35061-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Salloway, S., Sperling, R., Fox, N.C., et al. (2014) Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease. The New England Journal of Medicine, 370, 322-333. &lt;br&gt;https://doi.org/10.1056/NEJMoa1304839</mixed-citation></ref><ref id="hanspub.35061-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Yu, Y.J., Atwal, J.K., Zhang, Y., et al. (2014) Therapeutic Bispecific Antibodies Cross the Blood-Brain Barrier in Nonhuman Primates. Science Translational Medicine, 6, 261ra154. &lt;br&gt;https://doi.org/10.1126/scitranslmed.3009835</mixed-citation></ref><ref id="hanspub.35061-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Sonoda, H., Morimoto, H., Yoden, E., et al. (2018) A Blood-Brain-Barrier-Penetrating Anti-Human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II. Molecular Therapy, 26, 1366-1374. 
&lt;br&gt;https://doi.org/10.1016/j.ymthe.2018.02.032</mixed-citation></ref><ref id="hanspub.35061-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Okuyama, T., Eto, Y., Sakai, N., et al. (2019) Idu-ronate-2-Sulfatase with Anti-Human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial. Molecular Therapy, 27, 456-464.  
&lt;br&gt;https://doi.org/10.1016/j.ymthe.2018.12.005</mixed-citation></ref><ref id="hanspub.35061-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Kim, S.-S., Rait, A., Kim, E., et al. (2014) A Nanoparticle Car-rying the p53 Gene Targets Tumors Including Cancer Stem Cells, Sensitizes Glioblastoma to Chemotherapy and Im-proves Survival. ACS Nano, 8, 5494-5514.  
&lt;br&gt;https://doi.org/10.1021/nn5014484</mixed-citation></ref><ref id="hanspub.35061-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Kim, S.-S., Rait, A., Kim, E., et al. (2015) A Tumor-Targeting p53 Nanodelivery System Limits Chemoresistance to Temozolomide Prolonging Survival in a Mouse Model of Glioblastoma Multiforme. Nanomedicine: Nanotechnology, Biology and Medicine, 11, 301-311. &lt;br&gt;https://doi.org/10.1016/j.nano.2014.09.005</mixed-citation></ref><ref id="hanspub.35061-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Ramalho, M.J., Sevin, E., Gosselet, F., et al. (2018) Recep-tor-Mediated PLGA Nanoparticles for Glioblastoma Multiforme Treatment. The International Journal of Pharmaceutics, 545, 84-92.  
&lt;br&gt;https://doi.org/10.1016/j.ijpharm.2018.04.062</mixed-citation></ref><ref id="hanspub.35061-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Marino, A., Almici, E., Migliorin, S., et al. (2019) Piezoelectric Barium Titanate Nanostimulators for the Treatment of Glioblastoma Multiforme. Journal of Colloid and Interface Science, 538, 449-461.  
&lt;br&gt;https://doi.org/10.1016/j.jcis.2018.12.014</mixed-citation></ref><ref id="hanspub.35061-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Leoh, L.S., Kim, Y.K., Candelaria, P.V., et al. (2018) Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. The Journal of Immunology, 200, 3485-3494. &lt;br&gt;https://doi.org/10.4049/jimmunol.1700787</mixed-citation></ref><ref id="hanspub.35061-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Daniels-Wells, T.R., Candelaria, P.V., Leoh, L.S., et al. (2020) An IgG1 Version of the Anti-Transferrin Receptor 1 Antibody ch128. 1 Shows Significant Antitumor Activity against Different Xenograft Models of Multiple Myeloma: A Brief Communication. Journal of Immunotherapy, 43, 48-52. &lt;br&gt;https://doi.org/10.1097/CJI.0000000000000304</mixed-citation></ref><ref id="hanspub.35061-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Daniels-Wells, T.R., Widney, D.P., Leoh, L.S., et al. (2015) Efficacy of an Anti-Transferrin Receptor Antibody against AIDS-Related Non-Hodgkin Lymphoma: A Brief Commu-nication. Journal of Immunotherapy, 38, 307. 
&lt;br&gt;https://doi.org/10.1097/CJI.0000000000000092</mixed-citation></ref><ref id="hanspub.35061-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Shimosaki, S., Nakahata, S., Ichikawa, T., et al. (2017) De-velopment of a Complete Human IgG Monoclonal Antibody to Transferrin Receptor 1 Targeted for Adult T-Cell Leu-kemia/Lymphoma. Biochemical and Biophysical Research Communications, 485, 144-151. &lt;br&gt;https://doi.org/10.1016/j.bbrc.2017.02.039</mixed-citation></ref><ref id="hanspub.35061-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X., Yi, B., Liu, Z., et al. (2020) Global, Regional and Na-tional Burden of Pancreatic Cancer, 1990 to 2017: Results from the Global Burden of Disease Study 2017. Pancrea-tology, 20, 462-469. 
&lt;br&gt;https://doi.org/10.1016/j.pan.2020.02.011</mixed-citation></ref><ref id="hanspub.35061-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Henry, K.E., Dacek, M.M., Dilling, T.R., et al. (2019) A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. Clinical Cancer Research, 25, 166-176.  
&lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-18-1485</mixed-citation></ref><ref id="hanspub.35061-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Sugyo, A., Tsuji, A.B., Sudo, H., et al. (2017) Uptake of 111In-Labeled Fully Human Monoclonal Antibody TSP-A18 Reflects Transferrin Receptor Expression in Normal Or-gans and Tissues of Mice. Oncology Reports, 37, 1529-1536. 
&lt;br&gt;https://doi.org/10.3892/or.2017.5412</mixed-citation></ref><ref id="hanspub.35061-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Sugyo, A., Tsuji, A.B., Sudo, H., et al. (2015) Preclinical Evaluation of 89Zr-Labeled Human Antitransferrin Receptor Monoclonal Antibody as a PET Probe Using a Pancreatic Cancer Mouse Model. Nuclear Medicine Communications, 36, 286-294. &lt;br&gt;https://doi.org/10.1097/MNM.0000000000000245</mixed-citation></ref><ref id="hanspub.35061-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Sugyo, A., Tsuji, A.B., Sudo, H., et al. (2015) Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models. PLoS ONE, 10, e0123761. &lt;br&gt;https://doi.org/10.1371/journal.pone.0123761</mixed-citation></ref><ref id="hanspub.35061-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Camp, E., Wang, C., Little, E., et al. (2013) Transferrin Receptor Targeting Nanomedicine Delivering Wild-Type p53 Gene Sensitizes Pancreatic Cancer to Gemcitabine Therapy. Cancer Gene Therapy, 20, 222-228. 
&lt;br&gt;https://doi.org/10.1038/cgt.2013.9</mixed-citation></ref><ref id="hanspub.35061-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Lyons, V.J., Helms, A. and Pappas, D. (2019) The Effect of Protein Ex-pression on Cancer Cell Capture Using the Human Transferrin Receptor (CD71) as an Affinity Ligand. Analytica Chimica Acta, 1076, 154-161. 
&lt;br&gt;https://doi.org/10.1016/j.aca.2019.05.040</mixed-citation></ref><ref id="hanspub.35061-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Li, W., Zhang, Y., Reynolds, C.P., et al. (2017) Microfluidic Sep-aration of Lymphoblasts for the Isolation of Acute Lymphoblastic Leukemia Using the Human Transferrin Receptor as a Capture Target. Analytical Chemistry, 89, 7340-7347. &lt;br&gt;https://doi.org/10.1016/j.aca.2019.05.040</mixed-citation></ref><ref id="hanspub.35061-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Lyons, V.J. and Pappas, D. (2019) Affinity Separation and Subsequent Terminal Differentiation of Acute Myeloid Leukemia Cells Using the Human Transferrin Receptor (CD71) as a Capture Target. Analyst, 144, 3369-3380. 
&lt;br&gt;https://doi.org/10.1039/C8AN02357C</mixed-citation></ref><ref id="hanspub.35061-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, H., Yang, Y., Li, X., et al. (2018) Frequency-Enhanced Transferrin Receptor Antibody-Labelled Microfluidic Chip (FETAL-Chip) Enables Efficient Enrichment of Circulating Nucleated Red Blood Cells for Non-Invasive Prenatal Diagnosis. Lab Chip, 18, 2749-2756. &lt;br&gt;https://doi.org/10.1039/C8LC00650D</mixed-citation></ref></ref-list></back></article>